FDA approves Abbott's TriClip device for tricuspid regurgitation repair in high-risk patients.
The FDA has approved Abbott Laboratories' TriClip device, a first-of-its-kind system for the repair of tricuspid regurgitation (TR), a condition causing blood to flow backward in the heart. The approval, based on data from the TRILUMINATE trial, allows the device to be used for patients with TR not suitable for open-heart surgery. TriClip is already approved for use in over 50 countries, including Canada and nations in Europe.
April 02, 2024
17 Articles